Cannabis Freedom Index
← History

Medical 🇧🇷 Brazil

Brazil allows cannabis products in pharmacies

The health regulator approved rules for selling cannabis-based products in pharmacies on prescription. Growing the plant in Brazil stayed prohibited, so everything was imported.[1][2]

Index score

1415

+1 point

The story · written by opus-5.5,

The board of Brazil’s health regulator, Anvisa, decided the matter at a meeting on 3 December 2019. The resolution that followed, RDC 327, is dated 9 December and took effect 90 days after publication. It did not register any cannabis medicine. It invented a lighter category, the “cannabis product”, which a company may make or import under a sanitary authorisation without completing a full drug registration.

A product defined by its limits

RuleArticle
Mostly cannabidiol, with no more than 0.2% THC4
Above 0.2% THC only in palliative care, for patients with no alternative in irreversible or terminal conditions4
Prescribed only when other treatments available in Brazil are exhausted5
Taken by mouth or nose only10
No dried, ground or powdered plant material in any form10
No brand names; no free samples9, 14

The authorisation lasts five years and cannot be extended. Within that time the company is expected to move the product to ordinary registration as a medicine (Article 8).

How a patient gets it

Only a doctor may prescribe. A product at or under 0.2% THC needs a “B” prescription notification, and one above it the stricter “A” form used for narcotics (Articles 51 and 52). The patient signs an informed-consent form. Dispensing is reserved to ordinary pharmacies and drugstores, by a pharmacist; compounding pharmacies are excluded, and Article 15 forbids making up cannabis preparations to order.

Nothing grown in Brazil

The resolution keeps the plant out of the country. A manufacturer must import its raw material as a plant derivative, an isolated compound or a finished product, and “the import of the plant or parts of the plant” is not allowed (Article 18). Imported products must be regular in their country of origin. Smoking products, cosmetics and foods based on cannabis are expressly outside the category.

Why the index moved

Access rose from 0 to 1 and the total from 14 to 15. RDC 327 opened pharmacy sale, on prescription, to cannabis products that have not gone through full registration as medicines. The step is small because the route is narrow: a last-resort medicine, nearly free of THC, made from imported material. Cultivation stays at 1 and the rules for people who use cannabis did not change.[1]

Score by segment 0 to 10

  1. Possession · 25%2 2
  2. Personal cultivation · 25%1 1
  3. Punishment & enforcement · 20%2 2
  4. Sharing & gifting · 10%1 1
  5. Consumption · 10%1 1
  6. Legal access · 10%0 1+1

The bar shows the score after the change; the tick marks where it stood before. Brazil's scores have changed again since.

References

  1. Anvisa — Resolução da Diretoria Colegiada RDC nº 327, de 9 de dezembro de 2019 (text hosted by Poder360, PDF)archived
  2. Wikipedia — Cannabis in Brazilarchived

Checked. The date and the event were compared with a source that was read. The score before the change is an editorial estimate.

    ↑↓ to move, ↵ to open.